Clinical Trial Update: Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study evaluating the combination of Interleukin-21 with an anti-PD-1 agent in solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Interleukin-21 (Interleukin-21)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Neoplasms by Site | Phase 1 | Status: COMPLETED